Rovers Sophie, Janssens Annelies, Raskin Jo, Pauwels Patrick, van Meerbeeck Jan P, Smits Evelien, Marcq Elly
Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, 2610 Wilrijk, Belgium.
Department of Thoracic Oncology, Antwerp University Hospital (UZA), 2650 Edegem, Belgium.
Biomedicines. 2022 Mar 14;10(3):673. doi: 10.3390/biomedicines10030673.
Malignant pleural mesothelioma (MPM) is a fatal cancer type that affects the membranes lining the lungs, and is causally associated with asbestos exposure. Until recently, the first-line treatment consisted of a combination of chemotherapeutics that only had a limited impact on survival, and had not been improved in decades. With the recent approval of combined immune checkpoint inhibition for MPM, promising new immunotherapeutic strategies are now emerging for this disease. In this review, we describe the current preclinical and clinical evidence of various immune checkpoint inhibitors in MPM. We will consider the advantages of combined immune checkpoint blockade in comparison with single agent checkpoint inhibitor drugs. Furthermore, recent evidence suggests a role for T cell immunoglobulin and ITIM domain (TIGIT), an inhibitory immunoreceptor, as a novel target for immunotherapy. As this novel immune checkpoint remains largely unexplored in mesothelioma, we will discuss the potential of TIGIT blockade as an alternative therapeutic approach for MPM. This review will emphasize the necessity for new and improved treatments for MPM, while highlighting the recent advances and future perspectives of combined immune checkpoint blockade, particularly aimed at PD-L1 and TIGIT.
恶性胸膜间皮瘤（MPM）是一种致命的癌症类型，会影响肺部的衬膜，且与接触石棉有因果关系。直到最近，一线治疗方案还是由多种化疗药物联合组成，这些药物对生存期的影响有限，并且几十年来都没有得到改善。随着联合免疫检查点抑制疗法最近被批准用于MPM治疗，针对这种疾病的有前景的新免疫治疗策略正在出现。在这篇综述中，我们描述了MPM中各种免疫检查点抑制剂目前的临床前和临床证据。我们将探讨联合免疫检查点阻断与单药检查点抑制剂药物相比的优势。此外，最近的证据表明，抑制性免疫受体T细胞免疫球蛋白和ITIM结构域（TIGIT）作为免疫治疗的新靶点具有重要作用。由于这种新型免疫检查点在间皮瘤中基本上尚未得到充分研究，我们将讨论阻断TIGIT作为MPM替代治疗方法的潜力。这篇综述将强调MPM需要新的和改进的治疗方法，同时突出联合免疫检查点阻断，特别是针对PD-L1和TIGIT的联合免疫检查点阻断的最新进展和未来前景。
